Oculis Holding AG (OISE:OCS) Other Financing: kr13,183.98 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OISE:OCS Oculis Holding AG OISE:OCS
26 GF Score
Price kr1,350.00
! 1 Warning Sign
View Full Analysis

What is Oculis Holding AG Other Financing?

Oculis Holding AG OISE:OCS -1.10% 26 Other Financing is kr13,183.98 Mil as of Mar. 2026. GuruFocus rates OISE:OCS with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Oculis Holding AG's Other Financing for the three months ended in Mar. 2026 was kr209.23 Mil.

Oculis Holding AG's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was kr13,183.98 Mil.

Oculis Holding AG Other Financing Historical Data

* Premium members only.

The historical data trend for Oculis Holding AG's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oculis Holding AG Other Financing Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial -108.28 -20.91 -836.35 98.64 1,312.47

Oculis Holding AG Quarterly Data
Dec20 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,922.09 103.42 -249.45 13,120.78 209.23
OISE:OCS
26GF Score
Oculis Holding AG OISE:OCS
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oculis Holding AG Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr13,183.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of kr13,183.98 Mil mean?
Oculis Holding AG (OISE:OCS) has a Other Financing of kr13,183.98 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Oculis Holding AG and its competitors.
Is Oculis Holding AG's Other Financing too high?
Oculis Holding AG's current Other Financing is kr13,183.98 Mil. Overall, Oculis Holding AG has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Oculis Holding AG's Other Financing compare to RIGL and GYRE?
Oculis Holding AG's Other Financing of kr13,183.98 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Oculis Holding AG and its competitors. Oculis Holding AG's current Other Financing is kr13,183.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oculis Holding AG stock overvalued right now?
Oculis Holding AG (OISE:OCS) has a current Other Financing of kr13,183.98 Mil. The current Other Financing is kr13,183.98 Mil. Oculis Holding AG's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Oculis Holding AG (OISE:OCS), the current Other Financing is kr13,183.98 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oculis Holding AG Business Description

Other Exchanges OCS:USACR5:Germany
Address Bahnhofstrasse 20, Zug, CHE, CH-6300
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
26GF Score

Get the complete analysis for OISE:OCS

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1,350.00
Price